SEC Form 4 · accession 0001179110-17-013874
Blueprint Medicines Corp · BPMC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeffrey W. Albers
Officer — CEO and President · Director
Period of report
Nov 6, 2017
Accepted (ET)
Nov 8, 2017 · 4:21 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001597264
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 6, 2017 | M | 24,514 | $1.87 | A | 30,000 | D | |
| Common StockF2 | Nov 6, 2017 | S | 400 | $73.89 | D | 29,600 | D | |
| Common StockF3 | Nov 6, 2017 | S | 1,999 | $72.91 | D | 27,601 | D | |
| Common StockF4 | Nov 6, 2017 | S | 2,600 | $71.67 | D | 25,001 | D | |
| Common StockF5 | Nov 6, 2017 | S | 7,432 | $70.40 | D | 17,569 | D | |
| Common StockF6 | Nov 6, 2017 | S | 16,469 | $69.74 | D | 1,100 | D | |
| Common StockF7 | Nov 6, 2017 | S | 1,100 | $68.95 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F8 | $1.87 | Nov 6, 2017 | M | 24,514 | D | — | Jul 30, 2024 | Common Stock | 24,514 | 825,034 | D |
Explanation of responses
- F1The sales reported on this Form 4 were effected pursuant to a trading plan adopted on December 17, 2016 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
- F2The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.46 to $74.42 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (7) to this Form 4.
- F3The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.65 to $73.35 per share.
- F4The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.23 to $72.13 per share.
- F5The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.13 to $71.12 per share.
- F6The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.13 to $70.12 per share.
- F7The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.65 to $69.10 per share.
- F8This option was granted on July 30, 2014. This option vested as follows: (i) 12,620 shares vested in two installments at a rate of 6,310 shares on December 21, 2015 and May 21, 2016; (ii) 35,871 shares vested in three installments at a rate of 11,957 on June 21, 2016, July 21, 2016 and August 21, 2016; and (iii) 4,983 shares vested on September 21, 2016.